Fundraising Fox

Mnemo Therapeutics

2 known investors

Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.

Investors · 2

Sofinnova PartnersParis · $540K – $27M
Casdin CapitalreportedNew York

In the news

Huge Series A in France Strengthens European Epigenetic Oncologylabiotech.eu · Jun 2021Mnemo raises $90 million series A to improve CAR T cellscen.acs.org · Jun 2021Funding Mnemo: Transatlantic startup closes $91M series A round for CAR T therapies targeting epigenetic antigens | 2021-06-16 | BioWorldbioworld.com · Jun 2021Institut Curie applauds the €75 million fundraising achieved by its spin-off Mnemo Therapeutics - Institut Curie - Espace pressepresse.curie.fr · Jun 2021Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platformprnewswire.com · Jun 2021Mnemo Therapeutics Raises €75M in Series A Fundingfinsmes.com · Jun 2021

Frequently asked questions

What does Mnemo Therapeutics do?
Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.
Who are Mnemo Therapeutics's investors?
Mnemo Therapeutics's investors include Sofinnova Partners, Casdin Capital.